Establishing a glutamine metabolism-based model for predicting the prognosis of low-grade glioma

Mingshi Zhang; Mingjun Li; Jinrui Liu; Zhicheng Gu; Yanmei Lu; Yu Long; Yuyi Hou

doi:10.3389/fgene.2022.1030837

Establishing a glutamine metabolism-based model for predicting the prognosis of low-grade glioma

Front Genet. 2022 Nov 22:13:1030837. doi: 10.3389/fgene.2022.1030837. eCollection 2022.

Authors

Mingshi Zhang¹, Mingjun Li¹, Jinrui Liu¹, Zhicheng Gu¹, Yanmei Lu¹, Yu Long¹, Yuyi Hou²

Affiliations

¹ Department of Neurosurgery, The First Affiliated Hospital of Jiamusi University, Jiamusi, China.
² Department of Stomatology, The First Affiliated Hospital of Jiamusi University, Jiamusi, China.

Abstract

Background: The natural history of patients with low-grade glioma (LGG) varies widely, but most patients eventually deteriorate, leading to poor prognostic outcomes. We aim to develop biological models that can accurately predict the outcome of LGG prognosis. Methods: Prognostic genes for glutamine metabolism were searched by univariate Cox regression, and molecular typing was constructed. Functional enrichment analysis was done to evaluate potential prognostic-related pathways by analyzing differential genes in different subtypes. Enrichment scores of specific gene sets in different subtypes were measured by gene set enrichment analysis. Different immune infiltration levels among subtypes were calculated using algorithms such as CIBERSORT and ESTIMATE. Gene expression levels of prognostic-related gene signatures of glutamine metabolism phenotypes were used to construct a RiskScore model. Receiver operating characteristic curve, decision curve and calibration curve analyses were used to evaluate the reliability and validity of the risk model. The decision tree model was used to determine the best predictor variable ultimately. Results: We found that C1 had the worst prognosis and the highest level of immune infiltration, among which the highest macrophage infiltration can be found in the M2 stage. Moreover, most of the pathways associated with tumor development, such as MYC_TARGETS_V1 and EPITHELIAL_MESENCHYMAL_TRANSITION, were significantly enriched in C1. The wild-type IDH and MGMT hypermethylation were the most abundant in C1. A five-gene risk model related to glutamine metabolism phenotype was established with good performance in both training and validation datasets. The final decision tree demonstrated the RiskScore model as the most significant predictor of prognostic outcomes in individuals with LGG. Conclusion: The RiskScore model related to glutamine metabolism can be an exceedingly accurate predictor for LGG patients, providing valuable suggestions for personalized treatment.

Keywords: decision tree; glutamine; low-grade glioma; molecular typing; prognostic model.